Stockreport

Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed

GRAIL, Inc.  (GRAL) 
PDF NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Grail, Inc. (NASDAQ: GRAL) lost approximately 50% of its market value after disclosing that the NHS Galleri randomized tri [Read more]